Overview
DLB market data
Price History
DLB price chart
Valuation & Profitability
- P/E (TTM)
- 25.60 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $2.62 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.78 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 2.3% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 16.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $48.26 – $75.66 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $5.8B · P/B 2.65 · P/S 4.27.
Company News
Stock Market Today: Amazon Jumps 15%, Apple Wipes Out $475 BillionBenzinga · Jul 31, 2026, 5:42 PM
Why Dolby Labs Stock Popped TodayThe Motley Fool · Jul 31, 2026, 5:01 PM
Dolby Laboratories shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results. Also, the company announced that its Board has approved increasing the size of its stock repurchase program by $350 million.Benzinga · Jul 31, 2026, 2:17 PM
AXT Posts Upbeat Q2 Earnings, Joins Newell Brands, SPX Technologies, Amazon And Other Big Stocks Moving Higher On FridayBenzinga · Jul 31, 2026, 2:05 PM
Dolby Laboratories Announces $350M Increase To Stock Repurchase Program, Bringing Amount Available For Future Repurchases To About $427MBenzinga · Jul 30, 2026, 8:53 PM
Dolby Laboratories Lowers FY2026 GAAP EPS Guidance from $2.66-$2.81 to $2.62-$2.77 vs $2.83 EstBenzinga · Jul 30, 2026, 8:32 PM
Dolby Laboratories Lowers FY2026 Adj EPS Guidance from $4.30-$4.45 to $4.25-$4.40 vs $4.30 Est; Narrows FY2026 Sales Guidance from $1.400B-$1.450B to $1.410B-$1.440B vs $1.407B EstBenzinga · Jul 30, 2026, 8:32 PM
Dolby Laboratories Sees Q4 GAAP EPS $0.78-$0.93 vs $0.79 EstBenzinga · Jul 30, 2026, 8:31 PM
Dolby Laboratories Sees Q4 Adj EPS $1.13-$1.28 vs $1.20 Est; Sees Sales $362.000M-$392.000M vs $351.950M EstBenzinga · Jul 30, 2026, 8:31 PM
Dolby Laboratories Q3 Adj. EPS $0.69 Beats $0.67 Estimate, Sales $304.995M Miss $311.960M EstimateBenzinga · Jul 30, 2026, 8:17 PM